Log in

NASDAQ:DRRX - DURECT Stock Price, Forecast & News

+0.06 (+4.00 %)
(As of 03/29/2020 04:06 AM ET)
Today's Range
Now: $1.56
50-Day Range
MA: $1.72
52-Week Range
Now: $1.56
Volume557,552 shs
Average Volume1.24 million shs
Market Capitalization$305.48 million
P/E RatioN/A
Dividend YieldN/A
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DRRX



Sales & Book Value

Annual Sales$29.56 million
Book Value$0.12 per share


Net Income$-20,580,000.00


Market Cap$305.48 million
Next Earnings Date5/5/2020 (Estimated)

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

DURECT (NASDAQ:DRRX) Frequently Asked Questions

How has DURECT's stock been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DRRX shares have decreased by 5.5% and is now trading at $1.56. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DURECT?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DURECT.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for DURECT.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings results on Tuesday, March, 3rd. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The specialty pharmaceutical company had revenue of $10.69 million for the quarter, compared to analyst estimates of $12.55 million. DURECT had a negative return on equity of 100.24% and a negative net margin of 69.61%. View DURECT's earnings history.

What price target have analysts set for DRRX?

5 brokers have issued twelve-month target prices for DURECT's shares. Their forecasts range from $2.10 to $5.50. On average, they expect DURECT's share price to reach $4.40 in the next twelve months. This suggests a possible upside of 182.1% from the stock's current price. View analysts' price targets for DURECT.

Has DURECT been receiving favorable news coverage?

News coverage about DRRX stock has trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DURECT earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutDURECT.

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Geron (GERN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Advanced Micro Devices (AMD), Immunomedics (IMMU) and Verastem (VSTM).

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.06%), Renaissance Technologies LLC (2.19%), Beirne Wealth Consulting Services LLC (0.86%), Geode Capital Management LLC (0.79%), Gagnon Securities LLC (0.61%) and Acadian Asset Management LLC (0.59%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder and Michael Arenberg. View institutional ownership trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Assenagon Asset Management S.A., Virtu Financial LLC, Gagnon Securities LLC, Cubist Systematic Strategies LLC, and Citigroup Inc.. View insider buying and selling activity for DURECT.

Which institutional investors are buying DURECT stock?

DRRX stock was acquired by a variety of institutional investors in the last quarter, including EAM Global Investors LLC, EAM Investors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, Panagora Asset Management Inc., Alpine Global Management LLC, and California Public Employees Retirement System. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder, and Michael Arenberg. View insider buying and selling activity for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.56.

How big of a company is DURECT?

DURECT has a market capitalization of $305.48 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe. View additional information about DURECT.

What is DURECT's official website?

The official website for DURECT is http://www.durect.com/.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.

MarketBeat Community Rating for DURECT (NASDAQ DRRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Economic Bubble

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel